Dogwood Therapeutics (DWTX) Operating Income (2020 - 2026)

Dogwood Therapeutics has reported Operating Income for 7 years, with the latest figure at -$14.1 million in Q2 2026.

• On a quarterly basis, Operating Income fell 258.48% year-over-year to -$14.1 million in Q2 2026; TTM through Jun 2026 was -$38.8 million, a 112.98% decrease from a year earlier, with the FY2025 full-year figure at -$28.0 million, down 128.74% from the prior year.
• Operating Income was -$14.1 million for Q2 2026 at Dogwood Therapeutics, down from -$5.1 million in the prior quarter.
• The five-year high for Operating Income was -$1.1 million in Q2 2024, with the low at -$15.8 million in Q3 2025.
• Average Operating Income over 5 years is -$4.3 million, with a median of -$3.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Income surged 60.69% in 2023, then plunged 587.0% in 2025.
• Over 5 years, Operating Income stood at -$2.1 million in 2022, then surged by 45.54% to -$1.1 million in 2023, then plunged by 562.68% to -$7.5 million in 2024, then jumped by 49.53% to -$3.8 million in 2025, then tumbled by 269.48% to -$14.1 million in 2026.
• The last three Operating Income figures came in at -$14.1 million (Q2 2026), -$5.1 million (Q1 2026), and -$3.8 million (Q4 2025), per Business Quant data.